XORTX Therapeutics Inc (TSE:XRTX) has released an update.
XORTX Therapeutics Inc. has unveiled groundbreaking discoveries in the field of Autosomal Dominant Polycystic Kidney Disease (ADPKD) at the Rare and Genetic Kidney Disease Summit. These findings highlight the role of genetic factors in disease progression and suggest a potential for personalized therapies targeting xanthine oxidase inhibition.
For further insights into TSE:XRTX stock, check out TipRanks’ Stock Analysis page.